http://www.mypharma-editions.com L'Info Industrie & Politique de Santé Wed, 15 Feb 2012 14:04:44 +0000 en hourly 1 http://wordpress.org/?v=3.3.1 http://www.mypharma-editions.com/vih-innavirvax-annonce-une-levee-de-fonds-de-37-millions-deuros http://www.mypharma-editions.com/vih-innavirvax-annonce-une-levee-de-fonds-de-37-millions-deuros#comments Mon, 13 Feb 2012 15:06:12 +0000 morgdave http://www.mypharma-editions.com/?p=23410 http://www.mypharma-editions.com/vih-innavirvax-annonce-une-levee-de-fonds-de-37-millions-deuros/feed 0 http://www.mypharma-editions.com/le-primperan-et-ses-generiques-contre-indiques-chez-les-moins-de-18-ans http://www.mypharma-editions.com/le-primperan-et-ses-generiques-contre-indiques-chez-les-moins-de-18-ans#comments Thu, 09 Feb 2012 08:54:37 +0000 morgdave http://www.mypharma-editions.com/?p=23374 http://www.mypharma-editions.com/le-primperan-et-ses-generiques-contre-indiques-chez-les-moins-de-18-ans/feed 0 http://www.mypharma-editions.com/cancer-du-sein-la-fda-accorde-une-procedure-dexamen-prioritaire-au-pertuzumab-de-roche http://www.mypharma-editions.com/cancer-du-sein-la-fda-accorde-une-procedure-dexamen-prioritaire-au-pertuzumab-de-roche#comments Thu, 09 Feb 2012 08:30:20 +0000 morgdave http://www.mypharma-editions.com/?p=23372 http://www.mypharma-editions.com/cancer-du-sein-la-fda-accorde-une-procedure-dexamen-prioritaire-au-pertuzumab-de-roche/feed 0 http://www.mypharma-editions.com/le-beneficerisque-de-stablon-de-servier-reste-favorable http://www.mypharma-editions.com/le-beneficerisque-de-stablon-de-servier-reste-favorable#comments Wed, 08 Feb 2012 11:06:20 +0000 morgdave http://www.mypharma-editions.com/?p=23362 http://www.mypharma-editions.com/le-beneficerisque-de-stablon-de-servier-reste-favorable/feed 0 http://www.mypharma-editions.com/sanofi-et-bristol-myers-squibb-recoivent-4422-millions-de-dollars-dapotex-dans-le-litige-plavix http://www.mypharma-editions.com/sanofi-et-bristol-myers-squibb-recoivent-4422-millions-de-dollars-dapotex-dans-le-litige-plavix#comments Wed, 08 Feb 2012 08:47:02 +0000 morgdave http://www.mypharma-editions.com/?p=23358 http://www.mypharma-editions.com/sanofi-et-bristol-myers-squibb-recoivent-4422-millions-de-dollars-dapotex-dans-le-litige-plavix/feed 0 http://www.mypharma-editions.com/migraine-lafssaps-emet-des-reserves-sur-le-desernil http://www.mypharma-editions.com/migraine-lafssaps-emet-des-reserves-sur-le-desernil#comments Tue, 07 Feb 2012 10:11:48 +0000 morgdave http://www.mypharma-editions.com/?p=23345 http://www.mypharma-editions.com/migraine-lafssaps-emet-des-reserves-sur-le-desernil/feed 0 http://www.mypharma-editions.com/alize-pharma-cede-une-licence-a-eusa-pharma-sur-son-programme-asparec http://www.mypharma-editions.com/alize-pharma-cede-une-licence-a-eusa-pharma-sur-son-programme-asparec#comments Mon, 06 Feb 2012 15:01:36 +0000 morgdave http://www.mypharma-editions.com/?p=23341 http://www.mypharma-editions.com/alize-pharma-cede-une-licence-a-eusa-pharma-sur-son-programme-asparec/feed 0 http://www.mypharma-editions.com/diabete-adocia-recoit-10-m-au-titre-de-son-accord-de-licence-avec-eli-lilly http://www.mypharma-editions.com/diabete-adocia-recoit-10-m-au-titre-de-son-accord-de-licence-avec-eli-lilly#comments Mon, 06 Feb 2012 09:40:38 +0000 morgdave http://www.mypharma-editions.com/?p=23335 http://www.mypharma-editions.com/diabete-adocia-recoit-10-m-au-titre-de-son-accord-de-licence-avec-eli-lilly/feed 0 http://www.mypharma-editions.com/ab-science-annonce-de-nouveaux-resultats-cliniques-pour-masitinib http://www.mypharma-editions.com/ab-science-annonce-de-nouveaux-resultats-cliniques-pour-masitinib#comments Thu, 02 Feb 2012 09:05:11 +0000 morgdave http://www.mypharma-editions.com/?p=23309 http://www.mypharma-editions.com/ab-science-annonce-de-nouveaux-resultats-cliniques-pour-masitinib/feed 0 http://www.mypharma-editions.com/polyarthrite-rhumatoide-accord-entre-astellas-et-ucb-pour-commercialiser-cimzia-au-japon http://www.mypharma-editions.com/polyarthrite-rhumatoide-accord-entre-astellas-et-ucb-pour-commercialiser-cimzia-au-japon#comments Wed, 01 Feb 2012 09:33:26 +0000 morgdave http://www.mypharma-editions.com/?p=23293 http://www.mypharma-editions.com/polyarthrite-rhumatoide-accord-entre-astellas-et-ucb-pour-commercialiser-cimzia-au-japon/feed 0 http://www.mypharma-editions.com/roche-feu-vert-de-la-fda-pour-erivedge-dans-le-carcinome-basocellulaire-avance http://www.mypharma-editions.com/roche-feu-vert-de-la-fda-pour-erivedge-dans-le-carcinome-basocellulaire-avance#comments Tue, 31 Jan 2012 08:18:22 +0000 morgdave http://www.mypharma-editions.com/?p=23266 http://www.mypharma-editions.com/roche-feu-vert-de-la-fda-pour-erivedge-dans-le-carcinome-basocellulaire-avance/feed 0 http://www.mypharma-editions.com/hormone-de-croissance-chez-lenfant-la-has-pour-le-maintien-au-remboursement http://www.mypharma-editions.com/hormone-de-croissance-chez-lenfant-la-has-pour-le-maintien-au-remboursement#comments Mon, 30 Jan 2012 10:03:28 +0000 morgdave http://www.mypharma-editions.com/?p=23240 http://www.mypharma-editions.com/hormone-de-croissance-chez-lenfant-la-has-pour-le-maintien-au-remboursement/feed 0 http://www.mypharma-editions.com/ipsen-prend-acte-du-deremboursement-de-tanakan-en-france http://www.mypharma-editions.com/ipsen-prend-acte-du-deremboursement-de-tanakan-en-france#comments Fri, 27 Jan 2012 07:47:57 +0000 morgdave http://www.mypharma-editions.com/?p=23220 http://www.mypharma-editions.com/ipsen-prend-acte-du-deremboursement-de-tanakan-en-france/feed 0 http://www.mypharma-editions.com/vih-gilead-lance-un-essai-clinique-de-phase-2-evaluant-gs-7340 http://www.mypharma-editions.com/vih-gilead-lance-un-essai-clinique-de-phase-2-evaluant-gs-7340#comments Thu, 26 Jan 2012 09:27:02 +0000 morgdave http://www.mypharma-editions.com/?p=23210 http://www.mypharma-editions.com/vih-gilead-lance-un-essai-clinique-de-phase-2-evaluant-gs-7340/feed 0 http://www.mypharma-editions.com/vivalis-inaugure-un-laboratoire-dedie-a-sa-plateforme-de-decouverte-danticorps-monoclonaux-vivascreen http://www.mypharma-editions.com/vivalis-inaugure-un-laboratoire-dedie-a-sa-plateforme-de-decouverte-danticorps-monoclonaux-vivascreen#comments Wed, 25 Jan 2012 09:18:53 +0000 morgdave http://www.mypharma-editions.com/?p=23185 http://www.mypharma-editions.com/vivalis-inaugure-un-laboratoire-dedie-a-sa-plateforme-de-decouverte-danticorps-monoclonaux-vivascreen/feed 0 http://www.mypharma-editions.com/merck-serono-feu-vert-de-lue-pour-une-extension-dindication-de-rebif http://www.mypharma-editions.com/merck-serono-feu-vert-de-lue-pour-une-extension-dindication-de-rebif#comments Wed, 25 Jan 2012 08:23:41 +0000 morgdave http://www.mypharma-editions.com/?p=23179 http://www.mypharma-editions.com/merck-serono-feu-vert-de-lue-pour-une-extension-dindication-de-rebif/feed 0 http://www.mypharma-editions.com/santhera-et-ipsen-renegocient-leur-accord-de-licence-sur-le-fipamezole http://www.mypharma-editions.com/santhera-et-ipsen-renegocient-leur-accord-de-licence-sur-le-fipamezole#comments Tue, 24 Jan 2012 08:28:37 +0000 morgdave http://www.mypharma-editions.com/?p=23166 http://www.mypharma-editions.com/santhera-et-ipsen-renegocient-leur-accord-de-licence-sur-le-fipamezole/feed 0 http://www.mypharma-editions.com/genzyme-la-fda-approuve-a-son-tour-le-site-de-production-de-framingham http://www.mypharma-editions.com/genzyme-la-fda-approuve-a-son-tour-le-site-de-production-de-framingham#comments Tue, 24 Jan 2012 08:04:45 +0000 morgdave http://www.mypharma-editions.com/?p=23163 http://www.mypharma-editions.com/genzyme-la-fda-approuve-a-son-tour-le-site-de-production-de-framingham/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-deux-nouvelles-etapes-cles-pour-sa-biotherapie-amep-dans-le-melanome-metastatique http://www.mypharma-editions.com/bioalliance-pharma-deux-nouvelles-etapes-cles-pour-sa-biotherapie-amep-dans-le-melanome-metastatique#comments Mon, 23 Jan 2012 17:22:09 +0000 morgdave http://www.mypharma-editions.com/?p=23158 http://www.mypharma-editions.com/bioalliance-pharma-deux-nouvelles-etapes-cles-pour-sa-biotherapie-amep-dans-le-melanome-metastatique/feed 0 http://www.mypharma-editions.com/avis-favorable-du-chmp-pour-remicade-en-europe-pour-la-rectocolite-hemorragique-chez-les-patients-pediatriques http://www.mypharma-editions.com/avis-favorable-du-chmp-pour-remicade-en-europe-pour-la-rectocolite-hemorragique-chez-les-patients-pediatriques#comments Mon, 23 Jan 2012 07:58:16 +0000 morgdave http://www.mypharma-editions.com/?p=23122 http://www.mypharma-editions.com/avis-favorable-du-chmp-pour-remicade-en-europe-pour-la-rectocolite-hemorragique-chez-les-patients-pediatriques/feed 0 http://www.mypharma-editions.com/la-fda-met-a-jour-letiquetage-de-tysabri-natalizumab http://www.mypharma-editions.com/la-fda-met-a-jour-letiquetage-de-tysabri-natalizumab#comments Mon, 23 Jan 2012 07:52:00 +0000 morgdave http://www.mypharma-editions.com/?p=23119 http://www.mypharma-editions.com/la-fda-met-a-jour-letiquetage-de-tysabri-natalizumab/feed 0 http://www.mypharma-editions.com/gilenya-lema-lance-une-reevaluation-du-rapport-beneficesrisques http://www.mypharma-editions.com/gilenya-lema-lance-une-reevaluation-du-rapport-beneficesrisques#comments Fri, 20 Jan 2012 15:16:54 +0000 morgdave http://www.mypharma-editions.com/?p=23112 http://www.mypharma-editions.com/gilenya-lema-lance-une-reevaluation-du-rapport-beneficesrisques/feed 0 http://www.mypharma-editions.com/vih-feu-vert-de-la-fda-pour-de-nouvelles-formulations-de-viread-pour-les-enfants-infectes http://www.mypharma-editions.com/vih-feu-vert-de-la-fda-pour-de-nouvelles-formulations-de-viread-pour-les-enfants-infectes#comments Fri, 20 Jan 2012 12:04:54 +0000 morgdave http://www.mypharma-editions.com/?p=23098 http://www.mypharma-editions.com/vih-feu-vert-de-la-fda-pour-de-nouvelles-formulations-de-viread-pour-les-enfants-infectes/feed 0 http://www.mypharma-editions.com/astellas-feu-vert-au-japon-pour-regnite-contre-le-syndrome-des-jambes-sans-repos http://www.mypharma-editions.com/astellas-feu-vert-au-japon-pour-regnite-contre-le-syndrome-des-jambes-sans-repos#comments Thu, 19 Jan 2012 09:00:04 +0000 morgdave http://www.mypharma-editions.com/?p=23074 http://www.mypharma-editions.com/astellas-feu-vert-au-japon-pour-regnite-contre-le-syndrome-des-jambes-sans-repos/feed 0 http://www.mypharma-editions.com/sanofi-pasteur-le-bresil-introduit-le-vaccin-polio-inactive-dans-son-programme-national-de-vaccination http://www.mypharma-editions.com/sanofi-pasteur-le-bresil-introduit-le-vaccin-polio-inactive-dans-son-programme-national-de-vaccination#comments Thu, 19 Jan 2012 07:52:32 +0000 morgdave http://www.mypharma-editions.com/?p=23068 http://www.mypharma-editions.com/sanofi-pasteur-le-bresil-introduit-le-vaccin-polio-inactive-dans-son-programme-national-de-vaccination/feed 0 http://www.mypharma-editions.com/alzheimer-pfizer-et-medivation-abandonnent-le-developpement-du-dimebon http://www.mypharma-editions.com/alzheimer-pfizer-et-medivation-abandonnent-le-developpement-du-dimebon#comments Wed, 18 Jan 2012 10:09:20 +0000 morgdave http://www.mypharma-editions.com/?p=23055 http://www.mypharma-editions.com/alzheimer-pfizer-et-medivation-abandonnent-le-developpement-du-dimebon/feed 0 http://www.mypharma-editions.com/maladies-infectieuses-vivalis-et-sanofi-pasteur-etendent-leur-accord-de-collboration http://www.mypharma-editions.com/maladies-infectieuses-vivalis-et-sanofi-pasteur-etendent-leur-accord-de-collboration#comments Wed, 18 Jan 2012 08:25:21 +0000 morgdave http://www.mypharma-editions.com/?p=23046 http://www.mypharma-editions.com/maladies-infectieuses-vivalis-et-sanofi-pasteur-etendent-leur-accord-de-collboration/feed 0 http://www.mypharma-editions.com/genzyme-son-site-de-production-de-framingham-approuve-par-les-autorites-europeennes http://www.mypharma-editions.com/genzyme-son-site-de-production-de-framingham-approuve-par-les-autorites-europeennes#comments Wed, 18 Jan 2012 08:16:58 +0000 morgdave http://www.mypharma-editions.com/?p=23043 http://www.mypharma-editions.com/genzyme-son-site-de-production-de-framingham-approuve-par-les-autorites-europeennes/feed 0 http://www.mypharma-editions.com/benzodiazepines-lafssaps-dresse-un-etat-des-lieux-de-la-consommation-en-france http://www.mypharma-editions.com/benzodiazepines-lafssaps-dresse-un-etat-des-lieux-de-la-consommation-en-france#comments Tue, 17 Jan 2012 08:41:55 +0000 morgdave http://www.mypharma-editions.com/?p=23031 http://www.mypharma-editions.com/benzodiazepines-lafssaps-dresse-un-etat-des-lieux-de-la-consommation-en-france/feed 0 http://www.mypharma-editions.com/retraits-de-lots-de-medicaments-de-genopharm http://www.mypharma-editions.com/retraits-de-lots-de-medicaments-de-genopharm#comments Thu, 12 Jan 2012 08:32:36 +0000 morgdave http://www.mypharma-editions.com/?p=22983 http://www.mypharma-editions.com/retraits-de-lots-de-medicaments-de-genopharm/feed 0 http://www.mypharma-editions.com/ipsogen-acquier-les-droits-exclusifs-et-mondiaux-sur-deux-nouveaux-biomarqueurs http://www.mypharma-editions.com/ipsogen-acquier-les-droits-exclusifs-et-mondiaux-sur-deux-nouveaux-biomarqueurs#comments Tue, 10 Jan 2012 17:47:25 +0000 morgdave http://www.mypharma-editions.com/?p=22964 http://www.mypharma-editions.com/ipsogen-acquier-les-droits-exclusifs-et-mondiaux-sur-deux-nouveaux-biomarqueurs/feed 0 http://www.mypharma-editions.com/epilepsie-premiers-resultats-positifs-dans-letude-phase-ii-sur-vimpat-ducb http://www.mypharma-editions.com/epilepsie-premiers-resultats-positifs-dans-letude-phase-ii-sur-vimpat-ducb#comments Mon, 09 Jan 2012 08:42:04 +0000 morgdave http://www.mypharma-editions.com/?p=22943 http://www.mypharma-editions.com/epilepsie-premiers-resultats-positifs-dans-letude-phase-ii-sur-vimpat-ducb/feed 0 http://www.mypharma-editions.com/neovacs-letude-clinique-de-phase-iia-dans-la-polyarthrite-rhumatoide-atteint-ses-objectifs http://www.mypharma-editions.com/neovacs-letude-clinique-de-phase-iia-dans-la-polyarthrite-rhumatoide-atteint-ses-objectifs#comments Thu, 05 Jan 2012 08:27:09 +0000 morgdave http://www.mypharma-editions.com/?p=22929 http://www.mypharma-editions.com/neovacs-letude-clinique-de-phase-iia-dans-la-polyarthrite-rhumatoide-atteint-ses-objectifs/feed 1 http://www.mypharma-editions.com/bioalliance-pharma-nouvelles-avancees-dans-sa-collaboration-europeenne-avec-therabel http://www.mypharma-editions.com/bioalliance-pharma-nouvelles-avancees-dans-sa-collaboration-europeenne-avec-therabel#comments Wed, 04 Jan 2012 17:39:16 +0000 morgdave http://www.mypharma-editions.com/?p=22924 http://www.mypharma-editions.com/bioalliance-pharma-nouvelles-avancees-dans-sa-collaboration-europeenne-avec-therabel/feed 0 http://www.mypharma-editions.com/biogen-idec-et-isis-pharmaceuticals-vont-developper-un-programme-antisens-ciblant-latrophie-musculaire-spinale http://www.mypharma-editions.com/biogen-idec-et-isis-pharmaceuticals-vont-developper-un-programme-antisens-ciblant-latrophie-musculaire-spinale#comments Wed, 04 Jan 2012 15:27:22 +0000 morgdave http://www.mypharma-editions.com/?p=22920 http://www.mypharma-editions.com/biogen-idec-et-isis-pharmaceuticals-vont-developper-un-programme-antisens-ciblant-latrophie-musculaire-spinale/feed 0 http://www.mypharma-editions.com/recherche-clinique-quintiles-lance-son-unite-de-soins-numerique http://www.mypharma-editions.com/recherche-clinique-quintiles-lance-son-unite-de-soins-numerique#comments Wed, 04 Jan 2012 08:07:21 +0000 morgdave http://www.mypharma-editions.com/?p=22914 http://www.mypharma-editions.com/recherche-clinique-quintiles-lance-son-unite-de-soins-numerique/feed 5 http://www.mypharma-editions.com/roche-feu-vert-de-lue-pour-avastin-dans-le-cancer-de-lovaire http://www.mypharma-editions.com/roche-feu-vert-de-lue-pour-avastin-dans-le-cancer-de-lovaire#comments Fri, 23 Dec 2011 10:23:33 +0000 morgdave http://www.mypharma-editions.com/?p=22894 http://www.mypharma-editions.com/roche-feu-vert-de-lue-pour-avastin-dans-le-cancer-de-lovaire/feed 0 http://www.mypharma-editions.com/arret-de-letude-clinique-altitude-avec-rasilez http://www.mypharma-editions.com/arret-de-letude-clinique-altitude-avec-rasilez#comments Thu, 22 Dec 2011 16:09:05 +0000 morgdave http://www.mypharma-editions.com/?p=22892 http://www.mypharma-editions.com/arret-de-letude-clinique-altitude-avec-rasilez/feed 0 http://www.mypharma-editions.com/sanofi-la-fda-renforce-lavertissement-sur-le-multaq http://www.mypharma-editions.com/sanofi-la-fda-renforce-lavertissement-sur-le-multaq#comments Wed, 21 Dec 2011 11:25:21 +0000 morgdave http://www.mypharma-editions.com/?p=22851 http://www.mypharma-editions.com/sanofi-la-fda-renforce-lavertissement-sur-le-multaq/feed 0 http://www.mypharma-editions.com/maladie-de-parkinson-proteotech-et-glaxosmithkline-collaborent-au-developpement-dune-nouvelle-therapie http://www.mypharma-editions.com/maladie-de-parkinson-proteotech-et-glaxosmithkline-collaborent-au-developpement-dune-nouvelle-therapie#comments Tue, 20 Dec 2011 16:42:07 +0000 morgdave http://www.mypharma-editions.com/?p=22837 http://www.mypharma-editions.com/maladie-de-parkinson-proteotech-et-glaxosmithkline-collaborent-au-developpement-dune-nouvelle-therapie/feed 1 http://www.mypharma-editions.com/genzyme-premiers-resultats-de-letude-tenere-sur-le-teriflunomide-dans-la-sclerose-en-plaques http://www.mypharma-editions.com/genzyme-premiers-resultats-de-letude-tenere-sur-le-teriflunomide-dans-la-sclerose-en-plaques#comments Tue, 20 Dec 2011 08:36:55 +0000 morgdave http://www.mypharma-editions.com/?p=22824 http://www.mypharma-editions.com/genzyme-premiers-resultats-de-letude-tenere-sur-le-teriflunomide-dans-la-sclerose-en-plaques/feed 0 http://www.mypharma-editions.com/rhume-et-vasoconstricteurs-lafssaps-rappelle-les-recommandations-de-bon-usage http://www.mypharma-editions.com/rhume-et-vasoconstricteurs-lafssaps-rappelle-les-recommandations-de-bon-usage#comments Mon, 19 Dec 2011 14:04:23 +0000 morgdave http://www.mypharma-editions.com/?p=22819 http://www.mypharma-editions.com/rhume-et-vasoconstricteurs-lafssaps-rappelle-les-recommandations-de-bon-usage/feed 0 http://www.mypharma-editions.com/psoriasis-hybrigenics-acheve-le-recrutement-de-letude-clinique-de-phase-ii-de-linecalcitol http://www.mypharma-editions.com/psoriasis-hybrigenics-acheve-le-recrutement-de-letude-clinique-de-phase-ii-de-linecalcitol#comments Mon, 19 Dec 2011 13:53:05 +0000 morgdave http://www.mypharma-editions.com/?p=22815 http://www.mypharma-editions.com/psoriasis-hybrigenics-acheve-le-recrutement-de-letude-clinique-de-phase-ii-de-linecalcitol/feed 0 http://www.mypharma-editions.com/vih-le-test-de-depistage-de-roche-pour-lhypersensibilite-a-labacavir-disponible-en-europe http://www.mypharma-editions.com/vih-le-test-de-depistage-de-roche-pour-lhypersensibilite-a-labacavir-disponible-en-europe#comments Mon, 19 Dec 2011 09:51:29 +0000 morgdave http://www.mypharma-editions.com/?p=22811 http://www.mypharma-editions.com/vih-le-test-de-depistage-de-roche-pour-lhypersensibilite-a-labacavir-disponible-en-europe/feed 0 http://www.mypharma-editions.com/roche-recoit-un-avis-favorable-du-chmp-pour-zelboraf http://www.mypharma-editions.com/roche-recoit-un-avis-favorable-du-chmp-pour-zelboraf#comments Fri, 16 Dec 2011 13:38:16 +0000 morgdave http://www.mypharma-editions.com/?p=22799 http://www.mypharma-editions.com/roche-recoit-un-avis-favorable-du-chmp-pour-zelboraf/feed 0 http://www.mypharma-editions.com/essai-clinique-un-nouveau-traitement-cible-pour-les-synovialo-sarcomes http://www.mypharma-editions.com/essai-clinique-un-nouveau-traitement-cible-pour-les-synovialo-sarcomes#comments Thu, 15 Dec 2011 17:21:10 +0000 morgdave http://www.mypharma-editions.com/?p=22787 http://www.mypharma-editions.com/essai-clinique-un-nouveau-traitement-cible-pour-les-synovialo-sarcomes/feed 0 http://www.mypharma-editions.com/maladie-de-crohn-neovacs-finalise-le-recrutement-de-patients-dans-letude-de-phase-ii-avec-le-tnf-kinoide http://www.mypharma-editions.com/maladie-de-crohn-neovacs-finalise-le-recrutement-de-patients-dans-letude-de-phase-ii-avec-le-tnf-kinoide#comments Thu, 15 Dec 2011 08:25:58 +0000 morgdave http://www.mypharma-editions.com/?p=22772 http://www.mypharma-editions.com/maladie-de-crohn-neovacs-finalise-le-recrutement-de-patients-dans-letude-de-phase-ii-avec-le-tnf-kinoide/feed 0 http://www.mypharma-editions.com/vih-reyataz-de-bms-autorise-chez-la-femme-enceinte-dans-lue http://www.mypharma-editions.com/vih-reyataz-de-bms-autorise-chez-la-femme-enceinte-dans-lue#comments Wed, 14 Dec 2011 11:06:03 +0000 morgdave http://www.mypharma-editions.com/?p=22758 http://www.mypharma-editions.com/vih-reyataz-de-bms-autorise-chez-la-femme-enceinte-dans-lue/feed 1 http://www.mypharma-editions.com/feu-vert-de-lue-pour-dificlir-dastellas-pharma http://www.mypharma-editions.com/feu-vert-de-lue-pour-dificlir-dastellas-pharma#comments Wed, 14 Dec 2011 10:49:31 +0000 morgdave http://www.mypharma-editions.com/?p=22755 http://www.mypharma-editions.com/feu-vert-de-lue-pour-dificlir-dastellas-pharma/feed 0 http://www.mypharma-editions.com/trophos-echec-de-l%e2%80%99olesoxime-dans-un-essai-de-phase-iii-dans-la-sla http://www.mypharma-editions.com/trophos-echec-de-l%e2%80%99olesoxime-dans-un-essai-de-phase-iii-dans-la-sla#comments Tue, 13 Dec 2011 10:00:22 +0000 morgdave http://www.mypharma-editions.com/?p=22717 http://www.mypharma-editions.com/trophos-echec-de-l%e2%80%99olesoxime-dans-un-essai-de-phase-iii-dans-la-sla/feed 0 http://www.mypharma-editions.com/vaccination-massive-contre-la-meningite-en-afrique http://www.mypharma-editions.com/vaccination-massive-contre-la-meningite-en-afrique#comments Tue, 13 Dec 2011 08:26:10 +0000 morgdave http://www.mypharma-editions.com/?p=22705 http://www.mypharma-editions.com/vaccination-massive-contre-la-meningite-en-afrique/feed 0 http://www.mypharma-editions.com/alzheimer-exonhit-lance-une-etude-observationnelle-sur-son-test-aclarusdx%c2%ae-en-france http://www.mypharma-editions.com/alzheimer-exonhit-lance-une-etude-observationnelle-sur-son-test-aclarusdx%c2%ae-en-france#comments Tue, 13 Dec 2011 07:42:47 +0000 morgdave http://www.mypharma-editions.com/?p=22703 http://www.mypharma-editions.com/alzheimer-exonhit-lance-une-etude-observationnelle-sur-son-test-aclarusdx%c2%ae-en-france/feed 0 http://www.mypharma-editions.com/vih-gilead-annonce-les-donnees-sur-deux-ans-dune-etude-pivot-de-phase-3-sur-lelvitegravir http://www.mypharma-editions.com/vih-gilead-annonce-les-donnees-sur-deux-ans-dune-etude-pivot-de-phase-3-sur-lelvitegravir#comments Mon, 12 Dec 2011 08:41:53 +0000 morgdave http://www.mypharma-editions.com/?p=22677 http://www.mypharma-editions.com/vih-gilead-annonce-les-donnees-sur-deux-ans-dune-etude-pivot-de-phase-3-sur-lelvitegravir/feed 1 http://www.mypharma-editions.com/celgene-une-etude-de-phase-i-sur-lazacitidine-orale-dans-la-leucemie-myeloide-aigue-presentee-a-l%e2%80%99ash http://www.mypharma-editions.com/celgene-une-etude-de-phase-i-sur-lazacitidine-orale-dans-la-leucemie-myeloide-aigue-presentee-a-l%e2%80%99ash#comments Mon, 12 Dec 2011 08:28:21 +0000 morgdave http://www.mypharma-editions.com/?p=22669 http://www.mypharma-editions.com/celgene-une-etude-de-phase-i-sur-lazacitidine-orale-dans-la-leucemie-myeloide-aigue-presentee-a-l%e2%80%99ash/feed 0 http://www.mypharma-editions.com/janssen-nouvelles-donnees-sur-lefficacite-de-velcade-presentees-au-congres-de-l%e2%80%99ash http://www.mypharma-editions.com/janssen-nouvelles-donnees-sur-lefficacite-de-velcade-presentees-au-congres-de-l%e2%80%99ash#comments Mon, 12 Dec 2011 08:22:44 +0000 morgdave http://www.mypharma-editions.com/?p=22667 http://www.mypharma-editions.com/janssen-nouvelles-donnees-sur-lefficacite-de-velcade-presentees-au-congres-de-l%e2%80%99ash/feed 0 http://www.mypharma-editions.com/cancer-du-sein-resultats-positifs-d%e2%80%99une-etude-pivot-de-phase-iii-sur-le-pertuzumab-de-roche http://www.mypharma-editions.com/cancer-du-sein-resultats-positifs-d%e2%80%99une-etude-pivot-de-phase-iii-sur-le-pertuzumab-de-roche#comments Thu, 08 Dec 2011 07:59:52 +0000 morgdave http://www.mypharma-editions.com/?p=22626 http://www.mypharma-editions.com/cancer-du-sein-resultats-positifs-d%e2%80%99une-etude-pivot-de-phase-iii-sur-le-pertuzumab-de-roche/feed 0 http://www.mypharma-editions.com/diabete-et-risque-de-cancer-une-meta-analyse-confirme-la-securite-de-lantus%c2%ae-de-sanofi http://www.mypharma-editions.com/diabete-et-risque-de-cancer-une-meta-analyse-confirme-la-securite-de-lantus%c2%ae-de-sanofi#comments Thu, 08 Dec 2011 07:40:15 +0000 morgdave http://www.mypharma-editions.com/?p=22623 http://www.mypharma-editions.com/diabete-et-risque-de-cancer-une-meta-analyse-confirme-la-securite-de-lantus%c2%ae-de-sanofi/feed 0 http://www.mypharma-editions.com/diabete-resultats-positifs-pour-lyxumia%c2%ae-de-sanofi http://www.mypharma-editions.com/diabete-resultats-positifs-pour-lyxumia%c2%ae-de-sanofi#comments Tue, 06 Dec 2011 08:59:53 +0000 morgdave http://www.mypharma-editions.com/?p=22587 http://www.mypharma-editions.com/diabete-resultats-positifs-pour-lyxumia%c2%ae-de-sanofi/feed 0 http://www.mypharma-editions.com/vih-le-cobicistat-de-gilead-atteint-son-objectif-principal-lors-dune-etude-decisive-de-phase-3 http://www.mypharma-editions.com/vih-le-cobicistat-de-gilead-atteint-son-objectif-principal-lors-dune-etude-decisive-de-phase-3#comments Tue, 06 Dec 2011 08:20:44 +0000 morgdave http://www.mypharma-editions.com/?p=22581 http://www.mypharma-editions.com/vih-le-cobicistat-de-gilead-atteint-son-objectif-principal-lors-dune-etude-decisive-de-phase-3/feed 0 http://www.mypharma-editions.com/pommades-ophtalmiques-a-base-d%e2%80%99oxyde-jaune-mercurique-un-rapport-beneficerisque-defavorable http://www.mypharma-editions.com/pommades-ophtalmiques-a-base-d%e2%80%99oxyde-jaune-mercurique-un-rapport-beneficerisque-defavorable#comments Mon, 05 Dec 2011 15:17:48 +0000 morgdave http://www.mypharma-editions.com/?p=22577 http://www.mypharma-editions.com/pommades-ophtalmiques-a-base-d%e2%80%99oxyde-jaune-mercurique-un-rapport-beneficerisque-defavorable/feed 0 http://www.mypharma-editions.com/paludisme-amm-europeenne-pour-leurartesim%c2%ae-de-l%e2%80%99italien-sigma-tau http://www.mypharma-editions.com/paludisme-amm-europeenne-pour-leurartesim%c2%ae-de-l%e2%80%99italien-sigma-tau#comments Thu, 01 Dec 2011 13:46:39 +0000 morgdave http://www.mypharma-editions.com/?p=22546 http://www.mypharma-editions.com/paludisme-amm-europeenne-pour-leurartesim%c2%ae-de-l%e2%80%99italien-sigma-tau/feed 0 http://www.mypharma-editions.com/ranbaxy-annonce-le-lancement-de-son-generique-du-lipitor-%c2%ae-aux-etats-unis http://www.mypharma-editions.com/ranbaxy-annonce-le-lancement-de-son-generique-du-lipitor-%c2%ae-aux-etats-unis#comments Thu, 01 Dec 2011 08:45:42 +0000 morgdave http://www.mypharma-editions.com/?p=22519 http://www.mypharma-editions.com/ranbaxy-annonce-le-lancement-de-son-generique-du-lipitor-%c2%ae-aux-etats-unis/feed 0 http://www.mypharma-editions.com/sabcs-2011-roche-presentera-de-nouvelles-donnees-sur-le-traitement-du-cancer-du-sein-her2-positif-au-san-antonio-breast-cancer-symposium-2011 http://www.mypharma-editions.com/sabcs-2011-roche-presentera-de-nouvelles-donnees-sur-le-traitement-du-cancer-du-sein-her2-positif-au-san-antonio-breast-cancer-symposium-2011#comments Wed, 30 Nov 2011 08:41:07 +0000 morgdave http://www.mypharma-editions.com/?p=22512 http://www.mypharma-editions.com/sabcs-2011-roche-presentera-de-nouvelles-donnees-sur-le-traitement-du-cancer-du-sein-her2-positif-au-san-antonio-breast-cancer-symposium-2011/feed 1 http://www.mypharma-editions.com/lutte-contre-le-paludisme-sanofi-poursuit-son-engagement http://www.mypharma-editions.com/lutte-contre-le-paludisme-sanofi-poursuit-son-engagement#comments Wed, 30 Nov 2011 08:30:05 +0000 morgdave http://www.mypharma-editions.com/?p=22509 http://www.mypharma-editions.com/lutte-contre-le-paludisme-sanofi-poursuit-son-engagement/feed 0 http://www.mypharma-editions.com/vih-gilead-recoit-une-amm-europeenne-pour-eviplera%c2%ae http://www.mypharma-editions.com/vih-gilead-recoit-une-amm-europeenne-pour-eviplera%c2%ae#comments Wed, 30 Nov 2011 08:09:12 +0000 morgdave http://www.mypharma-editions.com/?p=22507 http://www.mypharma-editions.com/vih-gilead-recoit-une-amm-europeenne-pour-eviplera%c2%ae/feed 0 http://www.mypharma-editions.com/diabete-feu-vert-europeen-pour-onglyza%c2%ae-de-bristol-myers-squibb-et-astrazeneca http://www.mypharma-editions.com/diabete-feu-vert-europeen-pour-onglyza%c2%ae-de-bristol-myers-squibb-et-astrazeneca#comments Mon, 28 Nov 2011 13:31:46 +0000 morgdave http://www.mypharma-editions.com/?p=22494 http://www.mypharma-editions.com/diabete-feu-vert-europeen-pour-onglyza%c2%ae-de-bristol-myers-squibb-et-astrazeneca/feed 0 http://www.mypharma-editions.com/hemophilie-le-partenaire-d%e2%80%99ipsen-inspiration-initie-la-seconde-etude-pivotale-de-phase-iii-avec-obi-1 http://www.mypharma-editions.com/hemophilie-le-partenaire-d%e2%80%99ipsen-inspiration-initie-la-seconde-etude-pivotale-de-phase-iii-avec-obi-1#comments Mon, 28 Nov 2011 07:33:05 +0000 morgdave http://www.mypharma-editions.com/?p=22488 http://www.mypharma-editions.com/hemophilie-le-partenaire-d%e2%80%99ipsen-inspiration-initie-la-seconde-etude-pivotale-de-phase-iii-avec-obi-1/feed 0 http://www.mypharma-editions.com/genfit-nouvelles-donnees-precliniques-positives-pour-le-gft505 http://www.mypharma-editions.com/genfit-nouvelles-donnees-precliniques-positives-pour-le-gft505#comments Sat, 26 Nov 2011 08:59:59 +0000 morgdave http://www.mypharma-editions.com/?p=22480 http://www.mypharma-editions.com/genfit-nouvelles-donnees-precliniques-positives-pour-le-gft505/feed 0 http://www.mypharma-editions.com/pharmaleads-annonce-lentree-en-phase-2-du-pl37-chef-de-file-dune-nouvelle-classe-danalgesiques http://www.mypharma-editions.com/pharmaleads-annonce-lentree-en-phase-2-du-pl37-chef-de-file-dune-nouvelle-classe-danalgesiques#comments Fri, 25 Nov 2011 14:17:42 +0000 morgdave http://www.mypharma-editions.com/?p=22477 http://www.mypharma-editions.com/pharmaleads-annonce-lentree-en-phase-2-du-pl37-chef-de-file-dune-nouvelle-classe-danalgesiques/feed 0 http://www.mypharma-editions.com/le-hcsp-recommande-la-poursuite-de-la-vaccination-hpv http://www.mypharma-editions.com/le-hcsp-recommande-la-poursuite-de-la-vaccination-hpv#comments Thu, 24 Nov 2011 17:42:58 +0000 morgdave http://www.mypharma-editions.com/?p=22469 http://www.mypharma-editions.com/le-hcsp-recommande-la-poursuite-de-la-vaccination-hpv/feed 0 http://www.mypharma-editions.com/lipitor-pfizer-se-prepare-a-la-perte-imminente-de-son-brevet http://www.mypharma-editions.com/lipitor-pfizer-se-prepare-a-la-perte-imminente-de-son-brevet#comments Thu, 24 Nov 2011 13:54:30 +0000 morgdave http://www.mypharma-editions.com/?p=22463 http://www.mypharma-editions.com/lipitor-pfizer-se-prepare-a-la-perte-imminente-de-son-brevet/feed 0 http://www.mypharma-editions.com/usa-merck-co-solde-les-poursuites-sur-vioxx-pour-950-millions-de-dollars http://www.mypharma-editions.com/usa-merck-co-solde-les-poursuites-sur-vioxx-pour-950-millions-de-dollars#comments Wed, 23 Nov 2011 13:50:05 +0000 morgdave http://www.mypharma-editions.com/?p=22446 http://www.mypharma-editions.com/usa-merck-co-solde-les-poursuites-sur-vioxx-pour-950-millions-de-dollars/feed 0 http://www.mypharma-editions.com/affaire-thiotepa-le-leem-saisit-son-comite-de-deontovigilance http://www.mypharma-editions.com/affaire-thiotepa-le-leem-saisit-son-comite-de-deontovigilance#comments Tue, 22 Nov 2011 14:31:22 +0000 morgdave http://www.mypharma-editions.com/?p=22436 http://www.mypharma-editions.com/affaire-thiotepa-le-leem-saisit-son-comite-de-deontovigilance/feed 0 http://www.mypharma-editions.com/pharnext-termine-le-recrutement-pour-son-essai-clinique-de-phase-ii-avec-son-1er-pleomedicament%e2%84%a2 http://www.mypharma-editions.com/pharnext-termine-le-recrutement-pour-son-essai-clinique-de-phase-ii-avec-son-1er-pleomedicament%e2%84%a2#comments Tue, 22 Nov 2011 08:59:50 +0000 morgdave http://www.mypharma-editions.com/?p=22418 http://www.mypharma-editions.com/pharnext-termine-le-recrutement-pour-son-essai-clinique-de-phase-ii-avec-son-1er-pleomedicament%e2%84%a2/feed 0 http://www.mypharma-editions.com/fibromyalgie-pierre-fabre-medicament-obtient-une-amm-en-australie-pour-le-milnacipran-joncia%c2%ae http://www.mypharma-editions.com/fibromyalgie-pierre-fabre-medicament-obtient-une-amm-en-australie-pour-le-milnacipran-joncia%c2%ae#comments Mon, 21 Nov 2011 12:42:52 +0000 morgdave http://www.mypharma-editions.com/?p=22405 http://www.mypharma-editions.com/fibromyalgie-pierre-fabre-medicament-obtient-une-amm-en-australie-pour-le-milnacipran-joncia%c2%ae/feed 1 http://www.mypharma-editions.com/psoriasis-hybrigenics-lance-l%e2%80%99etude-clinique-de-phase-ii-de-l%e2%80%99inecalcitol http://www.mypharma-editions.com/psoriasis-hybrigenics-lance-l%e2%80%99etude-clinique-de-phase-ii-de-l%e2%80%99inecalcitol#comments Mon, 21 Nov 2011 09:31:21 +0000 morgdave http://www.mypharma-editions.com/?p=22398 http://www.mypharma-editions.com/psoriasis-hybrigenics-lance-l%e2%80%99etude-clinique-de-phase-ii-de-l%e2%80%99inecalcitol/feed 0 http://www.mypharma-editions.com/roche-la-fda-retire-l%e2%80%99amm-d%e2%80%99avastin-dans-le-cancer-du-sein http://www.mypharma-editions.com/roche-la-fda-retire-l%e2%80%99amm-d%e2%80%99avastin-dans-le-cancer-du-sein#comments Mon, 21 Nov 2011 08:53:27 +0000 morgdave http://www.mypharma-editions.com/?p=22390 http://www.mypharma-editions.com/roche-la-fda-retire-l%e2%80%99amm-d%e2%80%99avastin-dans-le-cancer-du-sein/feed 0 http://www.mypharma-editions.com/sclerose-en-plaques-avis-favorable-du-chmp-pour-lextension-de-lindication-de-rebif%c2%ae-de-merck-serono http://www.mypharma-editions.com/sclerose-en-plaques-avis-favorable-du-chmp-pour-lextension-de-lindication-de-rebif%c2%ae-de-merck-serono#comments Mon, 21 Nov 2011 08:19:21 +0000 morgdave http://www.mypharma-editions.com/?p=22380 http://www.mypharma-editions.com/sclerose-en-plaques-avis-favorable-du-chmp-pour-lextension-de-lindication-de-rebif%c2%ae-de-merck-serono/feed 0 http://www.mypharma-editions.com/thiotepa-l%e2%80%99afssaps-fait-le-point-sur-les-mesures-prises http://www.mypharma-editions.com/thiotepa-l%e2%80%99afssaps-fait-le-point-sur-les-mesures-prises#comments Sat, 19 Nov 2011 09:00:06 +0000 morgdave http://www.mypharma-editions.com/?p=22364 http://www.mypharma-editions.com/thiotepa-l%e2%80%99afssaps-fait-le-point-sur-les-mesures-prises/feed 0 http://www.mypharma-editions.com/traitement-anti-vih-gilead-sciences-finalise-un-accord-avec-tibotec-pharmaceuticals http://www.mypharma-editions.com/traitement-anti-vih-gilead-sciences-finalise-un-accord-avec-tibotec-pharmaceuticals#comments Thu, 17 Nov 2011 08:39:05 +0000 morgdave http://www.mypharma-editions.com/?p=22333 http://www.mypharma-editions.com/traitement-anti-vih-gilead-sciences-finalise-un-accord-avec-tibotec-pharmaceuticals/feed 1 http://www.mypharma-editions.com/deremboursement-du-multaq-sanofi-desapprouve http://www.mypharma-editions.com/deremboursement-du-multaq-sanofi-desapprouve#comments Thu, 17 Nov 2011 08:20:40 +0000 morgdave http://www.mypharma-editions.com/?p=22327 http://www.mypharma-editions.com/deremboursement-du-multaq-sanofi-desapprouve/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-avancees-sur-la-commercialisation-de-loramyc%c2%ae http://www.mypharma-editions.com/bioalliance-pharma-avancees-sur-la-commercialisation-de-loramyc%c2%ae#comments Tue, 15 Nov 2011 09:44:50 +0000 morgdave http://www.mypharma-editions.com/?p=22281 http://www.mypharma-editions.com/bioalliance-pharma-avancees-sur-la-commercialisation-de-loramyc%c2%ae/feed 0 http://www.mypharma-editions.com/sclerose-en-plaques-genzyme-annonce-les-resultats-positifs-d%e2%80%99une-etude-de-phase-3-avec-alemtuzumab http://www.mypharma-editions.com/sclerose-en-plaques-genzyme-annonce-les-resultats-positifs-d%e2%80%99une-etude-de-phase-3-avec-alemtuzumab#comments Mon, 14 Nov 2011 08:13:29 +0000 morgdave http://www.mypharma-editions.com/?p=22249 http://www.mypharma-editions.com/sclerose-en-plaques-genzyme-annonce-les-resultats-positifs-d%e2%80%99une-etude-de-phase-3-avec-alemtuzumab/feed 0 http://www.mypharma-editions.com/herpes-resultats-encourageants-grace-aux-meganucleases-de-cellectis http://www.mypharma-editions.com/herpes-resultats-encourageants-grace-aux-meganucleases-de-cellectis#comments Mon, 14 Nov 2011 07:55:51 +0000 morgdave http://www.mypharma-editions.com/?p=22247 http://www.mypharma-editions.com/herpes-resultats-encourageants-grace-aux-meganucleases-de-cellectis/feed 0 http://www.mypharma-editions.com/pfizer-signe-avec-mylan-un-accord-de-licence-mondial-sur-seretide%c2%ae http://www.mypharma-editions.com/pfizer-signe-avec-mylan-un-accord-de-licence-mondial-sur-seretide%c2%ae#comments Sun, 13 Nov 2011 08:27:21 +0000 morgdave http://www.mypharma-editions.com/?p=22707 http://www.mypharma-editions.com/pfizer-signe-avec-mylan-un-accord-de-licence-mondial-sur-seretide%c2%ae/feed 0 http://www.mypharma-editions.com/cancer-de-la-peau-la-fda-accepte-le-depot-du-dossier-d%e2%80%99enregistrement-du-vismodegib-de-roche http://www.mypharma-editions.com/cancer-de-la-peau-la-fda-accepte-le-depot-du-dossier-d%e2%80%99enregistrement-du-vismodegib-de-roche#comments Fri, 11 Nov 2011 10:05:56 +0000 morgdave http://www.mypharma-editions.com/?p=22216 http://www.mypharma-editions.com/cancer-de-la-peau-la-fda-accepte-le-depot-du-dossier-d%e2%80%99enregistrement-du-vismodegib-de-roche/feed 0 http://www.mypharma-editions.com/sanofi-et-regeneron-resultats-preliminaires-positifs-de-phase-ii-dans-l%e2%80%99hypercholesterolemie-pour-un-anticorps-anti-pcsk9 http://www.mypharma-editions.com/sanofi-et-regeneron-resultats-preliminaires-positifs-de-phase-ii-dans-l%e2%80%99hypercholesterolemie-pour-un-anticorps-anti-pcsk9#comments Thu, 10 Nov 2011 08:23:43 +0000 morgdave http://www.mypharma-editions.com/?p=22201 http://www.mypharma-editions.com/sanofi-et-regeneron-resultats-preliminaires-positifs-de-phase-ii-dans-l%e2%80%99hypercholesterolemie-pour-un-anticorps-anti-pcsk9/feed 2 http://www.mypharma-editions.com/neovacs%c2%ae-succes-de-l%e2%80%99etude-de-phase-iii-sur-lifn%ce%b1-kinoide%c2%ae-dans-le-lupus http://www.mypharma-editions.com/neovacs%c2%ae-succes-de-l%e2%80%99etude-de-phase-iii-sur-lifn%ce%b1-kinoide%c2%ae-dans-le-lupus#comments Wed, 09 Nov 2011 09:19:48 +0000 morgdave http://www.mypharma-editions.com/?p=22176 http://www.mypharma-editions.com/neovacs%c2%ae-succes-de-l%e2%80%99etude-de-phase-iii-sur-lifn%ce%b1-kinoide%c2%ae-dans-le-lupus/feed 0 http://www.mypharma-editions.com/transgene-et-jennerex-donnees-positives-d%e2%80%99une-etude-de-phase-ii-de-jx594tg6006-dans-le-cancer-du-foie-avance http://www.mypharma-editions.com/transgene-et-jennerex-donnees-positives-d%e2%80%99une-etude-de-phase-ii-de-jx594tg6006-dans-le-cancer-du-foie-avance#comments Tue, 08 Nov 2011 08:25:43 +0000 morgdave http://www.mypharma-editions.com/?p=22148 http://www.mypharma-editions.com/transgene-et-jennerex-donnees-positives-d%e2%80%99une-etude-de-phase-ii-de-jx594tg6006-dans-le-cancer-du-foie-avance/feed 0 http://www.mypharma-editions.com/hepatite-b-chronique-gilead-annonce-cinq-ans-de-donnees-positives-sur-viread%c2%ae http://www.mypharma-editions.com/hepatite-b-chronique-gilead-annonce-cinq-ans-de-donnees-positives-sur-viread%c2%ae#comments Mon, 07 Nov 2011 08:05:07 +0000 morgdave http://www.mypharma-editions.com/?p=22123 http://www.mypharma-editions.com/hepatite-b-chronique-gilead-annonce-cinq-ans-de-donnees-positives-sur-viread%c2%ae/feed 1 http://www.mypharma-editions.com/ophtalmologie-visiotact-pharma-lance-rdretinal%c2%ae-un-complement-alimentaire-contre-les-effets-de-lhyperglycemie-chronique http://www.mypharma-editions.com/ophtalmologie-visiotact-pharma-lance-rdretinal%c2%ae-un-complement-alimentaire-contre-les-effets-de-lhyperglycemie-chronique#comments Mon, 07 Nov 2011 07:58:17 +0000 morgdave http://www.mypharma-editions.com/?p=22119 http://www.mypharma-editions.com/ophtalmologie-visiotact-pharma-lance-rdretinal%c2%ae-un-complement-alimentaire-contre-les-effets-de-lhyperglycemie-chronique/feed 0 http://www.mypharma-editions.com/maladie-d%e2%80%99alzheimer-servier-rachete-a-l%e2%80%99americain-cortex-les-droits-exclusifs-sur-un-medicament http://www.mypharma-editions.com/maladie-d%e2%80%99alzheimer-servier-rachete-a-l%e2%80%99americain-cortex-les-droits-exclusifs-sur-un-medicament#comments Sat, 05 Nov 2011 10:07:26 +0000 morgdave http://www.mypharma-editions.com/?p=22114 http://www.mypharma-editions.com/maladie-d%e2%80%99alzheimer-servier-rachete-a-l%e2%80%99americain-cortex-les-droits-exclusifs-sur-un-medicament/feed 0 http://www.mypharma-editions.com/les-medicaments-a-base-de-pioglitazone-toujours-suspendus-du-marche-francais http://www.mypharma-editions.com/les-medicaments-a-base-de-pioglitazone-toujours-suspendus-du-marche-francais#comments Sat, 05 Nov 2011 08:57:12 +0000 morgdave http://www.mypharma-editions.com/?p=22107 http://www.mypharma-editions.com/les-medicaments-a-base-de-pioglitazone-toujours-suspendus-du-marche-francais/feed 0 http://www.mypharma-editions.com/ginkgo-biloba-des-medicaments-peu-efficaces-selon-l%e2%80%99afssaps http://www.mypharma-editions.com/ginkgo-biloba-des-medicaments-peu-efficaces-selon-l%e2%80%99afssaps#comments Fri, 04 Nov 2011 15:00:43 +0000 morgdave http://www.mypharma-editions.com/?p=22088 http://www.mypharma-editions.com/ginkgo-biloba-des-medicaments-peu-efficaces-selon-l%e2%80%99afssaps/feed 0 http://www.mypharma-editions.com/cancer-du-foie-transgene-et-jennerex-annoncent-l%e2%80%99inclusion-du-premier-patient-dans-un-essai-clinique-de-phase-iib-sur-jx594tg6006 http://www.mypharma-editions.com/cancer-du-foie-transgene-et-jennerex-annoncent-l%e2%80%99inclusion-du-premier-patient-dans-un-essai-clinique-de-phase-iib-sur-jx594tg6006#comments Fri, 04 Nov 2011 12:06:45 +0000 morgdave http://www.mypharma-editions.com/?p=22086 http://www.mypharma-editions.com/cancer-du-foie-transgene-et-jennerex-annoncent-l%e2%80%99inclusion-du-premier-patient-dans-un-essai-clinique-de-phase-iib-sur-jx594tg6006/feed 0 http://www.mypharma-editions.com/usa-glaxosmithkline-va-verser-3-milliards-de-dollars-pour-mettre-fin-aux-poursuites-sur-avandia http://www.mypharma-editions.com/usa-glaxosmithkline-va-verser-3-milliards-de-dollars-pour-mettre-fin-aux-poursuites-sur-avandia#comments Thu, 03 Nov 2011 12:17:00 +0000 morgdave http://www.mypharma-editions.com/?p=22055 http://www.mypharma-editions.com/usa-glaxosmithkline-va-verser-3-milliards-de-dollars-pour-mettre-fin-aux-poursuites-sur-avandia/feed 0 http://www.mypharma-editions.com/mucoviscidose-resultats-prometteurs-pour-kalydeco%e2%84%a2-de-vertex http://www.mypharma-editions.com/mucoviscidose-resultats-prometteurs-pour-kalydeco%e2%84%a2-de-vertex#comments Thu, 03 Nov 2011 10:02:27 +0000 morgdave http://www.mypharma-editions.com/?p=22047 http://www.mypharma-editions.com/mucoviscidose-resultats-prometteurs-pour-kalydeco%e2%84%a2-de-vertex/feed 0 http://www.mypharma-editions.com/ipsen-cede-les-droits-en-amerique-du-nord-d%e2%80%99apokyn%c2%ae-a-britannia-pharmaceuticals http://www.mypharma-editions.com/ipsen-cede-les-droits-en-amerique-du-nord-d%e2%80%99apokyn%c2%ae-a-britannia-pharmaceuticals#comments Thu, 03 Nov 2011 07:56:36 +0000 morgdave http://www.mypharma-editions.com/?p=22043 http://www.mypharma-editions.com/ipsen-cede-les-droits-en-amerique-du-nord-d%e2%80%99apokyn%c2%ae-a-britannia-pharmaceuticals/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-clonidine-lauriad%e2%84%a2-obtient-le-statut-de-%c2%ab-medicament-orphelin-%c2%bb-en-europe http://www.mypharma-editions.com/bioalliance-pharma-clonidine-lauriad%e2%84%a2-obtient-le-statut-de-%c2%ab-medicament-orphelin-%c2%bb-en-europe#comments Wed, 02 Nov 2011 17:52:51 +0000 morgdave http://www.mypharma-editions.com/?p=22039 http://www.mypharma-editions.com/bioalliance-pharma-clonidine-lauriad%e2%84%a2-obtient-le-statut-de-%c2%ab-medicament-orphelin-%c2%bb-en-europe/feed 0 http://www.mypharma-editions.com/infarctus-aigu-du-myocarde-trophos-demarre-l%e2%80%99etude-de-phase-2-de-sa-nouvelle-molecule-tro40303 http://www.mypharma-editions.com/infarctus-aigu-du-myocarde-trophos-demarre-l%e2%80%99etude-de-phase-2-de-sa-nouvelle-molecule-tro40303#comments Wed, 02 Nov 2011 14:56:27 +0000 morgdave http://www.mypharma-editions.com/?p=22035 http://www.mypharma-editions.com/infarctus-aigu-du-myocarde-trophos-demarre-l%e2%80%99etude-de-phase-2-de-sa-nouvelle-molecule-tro40303/feed 0